cyc 202 has been researched along with Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chalupová, M; Hošek, J; Štarha, P; Suchý, P; Trávníček, Z; Vančo, J | 1 |
| Andera, L; Beranova, L; Bohmova, M; Gasova, Z; Ivanek, R; Klanova, M; Klener, P; Koc, M; Ludvikova, Z; Molinsky, J; Necas, E; Strnad, M; Trneny, M; Zivny, J | 1 |
2 other study(ies) available for cyc 202 and Lymphoma
| Article | Year |
|---|---|
Platinum(II)-oxalato complexes of seliciclib (CYC202) derivatives show different cellular effects and lesser adverse effects in mouse lymphoma model than cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Humans; Lymphoma; Male; Mice; Mice, Inbred DBA; Organoplatinum Compounds; Oxalates; Roscovitine | 2020 |
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Death Domain Receptor Signaling Adaptor Proteins; Fas Ligand Protein; Humans; Leukemia; Lymphoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2013 |